251 related articles for article (PubMed ID: 37515162)
1. Modulation of Reoviral Cytolysis (II): Cellular Stemness.
Bourhill T; Rohani L; Kumar M; Bose P; Rancourt D; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515162
[TBL] [Abstract][Full Text] [Related]
2. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection.
Bourhill T; Mori Y; Rancourt DE; Shmulevitz M; Johnston RN
Viruses; 2018 Aug; 10(8):. PubMed ID: 30103501
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Reoviral Cytolysis (I): Combination Therapeutics.
Mori Y; Nishikawa SG; Fratiloiu AR; Tsutsui M; Kataoka H; Joh T; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515160
[TBL] [Abstract][Full Text] [Related]
4. Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.
Twigger K; Roulstone V; Kyula J; Karapanagiotou EM; Syrigos KN; Morgan R; White C; Bhide S; Nuovo G; Coffey M; Thompson B; Jebar A; Errington F; Melcher AA; Vile RG; Pandha HS; Harrington KJ
BMC Cancer; 2012 Aug; 12():368. PubMed ID: 22920673
[TBL] [Abstract][Full Text] [Related]
5. Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.
Kawagishi T; Kanai Y; Nouda R; Fukui I; Nurdin JA; Matsuura Y; Kobayashi T
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907973
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
[TBL] [Abstract][Full Text] [Related]
7. Noncanonical Cell Death Induction by Reassortant Reovirus.
Rodríguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.
Babaei A; Soleimanjahi H; Soleimani M; Arefian E
Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878
[TBL] [Abstract][Full Text] [Related]
9. Reovirus safety study for proliferation and differentiation of human adipose-derived mesenchymal stem cells.
Park JS; Kim M
J Microbiol; 2017 Jan; 55(1):75-79. PubMed ID: 28035603
[TBL] [Abstract][Full Text] [Related]
10. Naturally occurring reoviruses for human cancer therapy.
Kim M
BMB Rep; 2015 Aug; 48(8):454-60. PubMed ID: 26058397
[TBL] [Abstract][Full Text] [Related]
11. Importin-β and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells.
Nuovo G; Tran H; Gutierrez A; Fadda P; Pichiorri F; Caserta E; Hofmeister CC; Chesi M; Leif Bergsagel P; Morris D; Shi Q; Coffey M; Thirukkumaran C
Ann Diagn Pathol; 2018 Feb; 32():28-34. PubMed ID: 29414394
[TBL] [Abstract][Full Text] [Related]
12. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
13. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
Kumar V; Giacomantonio MA; Gujar S
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920168
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR; Hofmeister CC
Clin Cancer Res; 2014 Dec; 20(23):5946-55. PubMed ID: 25294913
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
[TBL] [Abstract][Full Text] [Related]
16. Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models.
van de Merbel AF; van der Horst G; van der Mark MH; Bots STF; van den Wollenberg DJM; de Ridder CMA; Stuurman D; Aalders T; Erkens-Schulz S; van Montfoort N; Karthaus WR; Mehra N; Smits M; Schalken JA; van Weerden WM; Hoeben RC; van der Pluijm G
Cancer Gene Ther; 2022 Jun; 29(6):793-802. PubMed ID: 34135475
[TBL] [Abstract][Full Text] [Related]
17. Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis in vivo.
Kim M; Hansen KK; Davis L; van Marle G; Gill MJ; Fox JD; Hollenberg MD; Rancourt DE; Lee PW; Yun CO; Johnston RN
Antivir Ther; 2010; 15(6):897-905. PubMed ID: 20834102
[TBL] [Abstract][Full Text] [Related]
18. Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus.
Kemp V; Hoeben RC; van den Wollenberg DJ
Viruses; 2015 Dec; 8(1):. PubMed ID: 26712782
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of GSK-3beta enhances reovirus-induced apoptosis in colon cancer cells.
Min HJ; Koh SS; Cho IR; Srisuttee R; Park EH; Jhun BH; Kim YG; Oh S; Kwak JE; Johnston RN; Chung YH
Int J Oncol; 2009 Sep; 35(3):617-24. PubMed ID: 19639182
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery.
Kemp V; Dautzenberg IJC; Limpens RW; van den Wollenberg DJM; Hoeben RC
Viruses; 2017 Sep; 9(10):. PubMed ID: 28934149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
